Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups.
With life science exports topping EUR 20 billion and growing, Denmark looks set to retain its position as one of the European industry’s most prominent players. Indeed, Denmark is already Europe’s leading country in terms of clinical trials per capita, has long valued innovative public-private collaboration models, and sits proudly in first position in the World Bank’s Ease of Doing Business Index.
Through interviews with a host of stakeholders throughout the Danish healthcare value chain, this exclusive new report examines the fundamentals behind the country’s strong global positioning as well as the roadblocks ahead if the Nordic nation is to maintain it.
Topics covered include health technology assessment trends, the potential impact of a new national Life Science Strategy, how the country’s digital excellence has helped it navigate the COVID-19 pandemic, the benefits of the foundational model within which Denmark’s ‘Big Four’ pharma companies work, clinical trial collaboration with neighbouring Sweden, the Danish market’s potential as a testbed for innovative management strategies, and much more.